非小细胞肺癌免疫治疗持续用药规范化白皮书  

White paper on standardized continuous use of immunotherapy for non-small cell lung cancer

作　　者：中国临床肿瘤学会免疫治疗专家委员会 王宝成[2] 周彩存 段建春[4] 胡洁[5] 李国辉[4] 王俊 姚煜[7] Chinese Society of Clinical Oncology Expert Committee on Immunotherapy;WANG Baocheng

机构地区：[1]不详 [2]中国人民解放军联勤保障部队第960医院 [3]同济大学附属上海市肺科医院 [4]中国医学科学院肿瘤医院 [5]复旦大学附属中山医院 [6]山东第一医科大学第一附属医院 [7]西安交通大学第一附属医院

出　　处：《临床肿瘤学杂志》2024年第4期280-287,共8页Chinese Clinical Oncology

摘　　要：非小细胞肺癌(NSCLC)是我国发病率和死亡率最高的恶性肿瘤,疾病负担高,生存预后不佳。免疫检查点抑制剂(ICIs)为NSCLC系统性治疗带来了巨大突破,已成为驱动基因阴性NSCLC晚期一线、后线及围术期治疗的标准方案。然而,临床实践中免疫治疗持续用药时长与临床研究及指南推荐的治疗用药时长存在较大差距。为推动我国NSCLC免疫治疗规范化,提高NSCLC患者获益和总生存,中国临床肿瘤学会(CSCO)免疫治疗专家委员会联合领域专家共同发起NSCLC免疫治疗持续用药规范化项目,通过全国范围大样本调研揭示NSCLC免疫治疗规范化应用现状及临床问题,结合调研结果和现状分析形成专家倡议,为全国各层级医院免疫治疗的规范化应用提供指导。Non-small cell lung cancer(NSCLC)is a malignant tumor with the highest morbidity and mortality rates in China.The emergence of immune checkpoint inhibitors(ICIs)has brought great breakthroughs in NSCLC and has become the standard of care for advanced or early NSCLC without oncogenic driver mutations.However,the status of continuous use of NSCLC immunotherapy in China is obviously insufficient,and there is a large gap between the duration of NSCLC immunotherapy in current clinical practice and in clinical studies or clinical guidelines recommendations.In order to promote the standardized ICIs treatment,improve the benefits and overall survival of NSCLC patients,the Chinese Society of Clinical Oncology(CSCO)Immunotherapy Expert Committee,in collaboration with experts in the field,formulate the white paper on standardized continuous use of immunotherapy for NSCLC,aiming to reveal the status and issues of ICIs clinical use in different regions of China via a national questionnaire survey for oncologists,and form expert recommendations to provide guidance for standardized application of immunotherapy in hospitals at all levels nationwide.

关 键 词：非小细胞肺癌 免疫检查点抑制剂 免疫规范化治疗 白皮书 

分 类 号：R734.2[医药卫生—肿瘤]